Source: CORNELL UNIVERSITY submitted to NRP
ADVANCING NEONATAL VACCINATION STRATEGIES: A MOLECULAR APPROACH TO MONITOR IMMUNE RESPONSES
Sponsoring Institution
National Institute of Food and Agriculture
Project Status
COMPLETE
Funding Source
Reporting Frequency
Annual
Accession No.
0227842
Grant No.
2012-67015-19459
Cumulative Award Amt.
$397,202.00
Proposal No.
2011-02923
Multistate No.
(N/A)
Project Start Date
May 1, 2012
Project End Date
Apr 30, 2016
Grant Year
2012
Program Code
[A1221]- Animal Health and Production and Animal Products: Animal Health and Disease
Recipient Organization
CORNELL UNIVERSITY
(N/A)
ITHACA,NY 14853
Performing Department
Clinical Science
Non Technical Summary
Animal neonates are exposed to a multitude of pathogens at birth that require appropriate and life-long immune responses in a timely manner. Failure to do so may result in death; therefore, prevention and treatment of such infections are of importance in animal medicine. Despite great need, the value of preventative neonatal vaccination strategies is controversial: traditional concerns exist with the interference of passively transferred maternal antibodies and the level of immaturity of the innate and adaptive immune system at birth. However, fully mature, functional, and protective immune responses have been reported during the neonatal period after some types of vaccines, which suggest that the use of the appropriate strategy at this developmental stage is valuable. Vaccination in early life is also beneficial to veterinary medicine because it would likely decrease the period of susceptibility for individuals and entire herds. To attain the benefits of neonatal vaccination for horses and production animals, we need to understand the precise type of immune response generated and any effects of passively transferred maternal antibodies on neonatal immune responses, and then use that information to define the most effective vaccination strategies. This proposal investigates the immune response generated by neonates in response to vaccination in the presence and absence of passively transferred maternal antibodies. Specifically, this work investigates the potential for effective neonatal vaccination against equine influenza for its importance to domestic and production animals. Influenza vaccination is of concern for U.S. equine and livestock species for both health and economic considerations. Equine influenza is endemic in the U.S. equine population and is one of the most common infectious diseases of the respiratory tract. Adequate protection through vaccination is critical because horses that are partially immune can become subclinically infected and shed virus. In addition, this organism undergoes periodic antigenic drift, which challenges long-term development and evaluation of humoral immune protection. Therefore, assays that offer specific and precise information on both the quantity and quality of the immune response are paramount. Although we propose fundamental basic research, the implications of advancing effective vaccine strategies can be easily applied in practice to minimize the window of susceptibility for neonates with naive immune systems. We believe that the equine neonatal model and our approach of immunoglobulin heavy chain variable region sequence analysis will be insightful and add relevant information that can be judiciously tested and applied to vaccinology. A major value of this work is that it can be applied to any species and any pathogen to identify the quality and quantity of the humoral immune response.
Animal Health Component
50%
Research Effort Categories
Basic
25%
Applied
50%
Developmental
25%
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
3113810109050%
3113810105050%
Goals / Objectives
Goals: This project investigates the competence of neonatal antibody production in the presence or absence of circulating maternally-derived antibodies. The goal of this project is to evaluate neonatal immune responses to vaccines, based on B cell immunoglobulin heavy chain variable region (VDJ) sequence analysis, serum antibody levels, development of plasma and memory cells, and the function of antigen presenting cells in early life. Specifically, the proposed experiments investigate: 1) neonatal antibody production in response to protein vaccines; 2) diversity of the neonatal antibody repertoire; 3) how maternally-derived antibodies affect the production and diversity of antibodies in the neonate; 4) how the neonatal humoral response is improved with a vaccine booster; and 5) the concomitant function of antigen presenting cells. If our aims are achieved, we will demonstrate that antigen-specific humoral responses in the neonate can be generated in the presence of maternal antibodies. Expected outputs: Through abstract presentations and manuscript publications, the methodology developed in this study will be shared with the immunology community to help advance neonatal vaccination strategies. The use of B-cell immunoglobulin variable region sequence may detect markedly low levels of humoral response not measurable via more traditional serum antigen-specific antibody concentrations. If confirmed, the results from this study will change the perspective on neonatal vaccinology, and justify the development of vaccines for this age group. Importantly, immunoglobulin diversity will become a validated method to measure vaccine quality. With respect to specific results, we expect: 1) To detect diverse B cell-immunoglobulin variable region sequences in neonatal samples in response to vaccination, and expect the magnitude and diversity of the antibody response to increase in response to vaccine booster. 2) To detect neonatal antibody responses to vaccination despite the presence of maternal antibodies, with diverse immunoglobulin variable region sequences, and a corresponding increase in magnitude and diversity in response to vaccine booster. 3) Neonates to generate a measurable and diverse antibody response to influenza vaccination and booster, despite the presence of maternal antibodies. We also expect to detect B cell memory markers in neonatal samples, and a robust T cell recall to influenza stimulation. 4) To identify significant differences in dendritic cell activation by different antigenic structures, including co-stimulatory molecule and cytokine expression. Timeline: In year 1, we will vaccinate horses, isolate antigen-specific B cells, perform immunoglobulin sequence analysis, ELISA, and cell culture experiments, and freeze cells. With these initial samples, we will validate the B cell panning protocol, influenza-specific ELISA, and the CD38 quantitative PCR assay. In year 2, the remaining horses will be vaccinated and the corresponding experiments will be performed. By the end of year 2, assays for aims 1, 2, and 3 will be completed. In year 3, we will use frozen cells to perform the RNA-Seq experiments and analysis detailed in aim 4.
Project Methods
This project measures the magnitude and quality of the neonatal humoral immune response to vaccines using a novel approach of B-cell immunoglobulin variable region sequence. We expect this method to detect markedly low levels of humoral response not measurable via more traditional serum antigen-specific antibody concentrations (ELISA). In addition, immunoglobulin variable region sequence will reveal the extent of diversity present, an indicator of immune system development. In aim 1, 3-day-old neonates will be vaccinated with keyhole limpet hemocyanin (KLH), and boosted on day 28. Samples will be collected from vaccinated and control foals at different time points. Serum samples will be used to measure KLH-specific Ig levels, and KLH-specific B cells will be isolated from neonatal circulation for Ig variable region RT-PCR and sequencing. In aim 2, pregnant mares will be vaccinated with KLH 30 days prior to their foaling date, and thus KLH vaccination of 3 day old neonates will occur in the presence of maternal antibodies. The same schedule and assays will be used as above. In aim 3, the neonatal response to influenza vaccination will be assessed with the same schedule as in aim 1and influenza-specific assays. Memory B cells and plasma cells will be assessed by measuring CD27 and CD38 mRNA expression levels in the influenza-specific B cell population. The neonatal cellular immune response to influenza vaccine booster will be measured with in vitro lymphocyte proliferation and cytokine production assays. In aim 4, the effects of antigen composition (whole pathogen vs. antigen fragment) and age will be investigated. Dendritic cells (DC) differentiated in vitro will be stimulated with inactivated influenza whole organism, influenza HA protein, E.coli, lipopolysaccharide (LPS), or medium. Transcriptome sequencing will be performed on RNA harvested 24 hours post-exposure and gene expression profiles will be contrasted with respect to antigenic exposure and age. The results of aims 1, 2 and 3 (generation of Ig and extent of diversity) will be compared to elucidate the effect of maternal antibodies on the neonate's antigen-specific humoral response. Normally distributed data will be analyzed with Student's t-test. Non-normally distributed data will be analyzed using non-parametric techniques. Alpha will be 5%. For aim 4, RNA-Seq data will be analyzed in collaboration with the Computational Biology Service Unit at Cornell University. Ingenuity Pathway Analysis software will also be used to appreciate the biological relevance of differentially regulated genes. Significant differences will be validated with quantitative real-time RT-PCR. These results will reveal the neonatal DC capacity for recognition and processing of different types of antigen structure, and determine when their gene expression profile is equivalent to adult APCs.

Progress 05/01/12 to 04/30/16

Outputs
Target Audience:scientists, equine industry, animal production industry, professional students, veterinarians Changes/Problems:Overall, our study was delayed for 1 year due to a low number of equine offsprings in the early years of the award (due to the 2008 economic crisis), and a technical problem/personnel replacement in the Cornell Cell Sorting facility. All the proposed experiments were completed. The only change in the proposed experiments was in Aim 4, with the replacement of the transcriptome analysis for quantitative RT-PCR because stimulated dendritic cells in vitro yielded insufficient RNA for the transcriptome but quantity and quality were sufficient for quantitative RT-PCR of targeted genes relevant to antigen presentation and lymphocyte activation/modulation; final analyses are underway. Instead, peripheral blood samples from D3 and D42 foals were submitted for transcriptome and analyses of data are underway. Preliminary data indicates age-dependent expression of molecules that are involved in co-stimulation and activation of lymphocytes. What opportunities for training and professional development has the project provided?We have gained experience in performing, troubleshooting, and comparing cell-sorting methods (flow cytometry and magnetic cell sorting), antigen captureELISAs, immunoglobulin variable region gene sequencing andanalysis, transcriptome and geneanalysis.We learned about developmental humoral competence in the equine neonate. The individuals who obtained training and professional development through these studies were: Maria Julia Bevilaqua Felippe, MV, MS, PhD Rebecca Tallmadge, PhD Steven Miller, MS Understanding how vaccines work is relevant to humans and veterinary species because the neonatal phase is the first and likely the most important opportunity for providing health care and the administration of vaccines, both with life-long outcomes. Our project investigated the competence of neonatal antibody production in response to vaccination, in the presence or absence of circulating maternally-derived antibodies, using antigen-specific B cell antibody sequence. This innovative and sensitive method can be tailored and applied to any species, overcome the challenge of measuring the confounding levels of maternally-derived antibodies during early age, and reveal the effect of re-vaccination (booster) in the humoral immune response. In addition, the transcriptome analyses of equine neonate leukocytes and comparisons with equine adult leukocytes highlight key immune developmental characteristics in the neonatal phase that are relevant to vaccine response and immunity to pathogens. How have the results been disseminated to communities of interest?We reported our results to the scientific community in the annual USDA-NIFA AFRI Animal Health and Animal Welfare Project Director Workshops (from 2012-2015), and veterinary meetings: 2015 - Tallmadge RL, Felippe MJB. Assessing neonatal responses to vaccination at the protein and gene level: Ig and more Ig. Plant & Animal Genome Conference, PAG XXII, San Diego, CA. Abstract oral presentation on January 10, 2015, 5:05pm. 2015 - Tallmadge RL, Felippe MJB. Equine neonatal immunoglobulin production and diversity in response to vaccination. 5TH European Veterinary Immunology Workshop, Vienna, Austria. Abstract poster presentation,published in the programme and abstract book, page 113. Two manuscripts are being prepared with the data generated from this award. Their production comes after a delay in our project to obtainsufficient number of foals for the groups,and technical issues with and technician replacement for the cell sorter at the College. Once all the assays were processed (cell sorting and culture, monocyte differentiation into dendritic cells, lymphocyte proliferation) for all samples (foals and adult controls, different time points) in the third year of the award, subsequent analyses were performed and finalized for protein and gene expression (antigen-specific serum antibody ELISA, antigen-specific B cell IgM and IgG variable region sequencing and CDR3 length distribution, memory B cell quantification, cytokine expression of stimulated cells) in the forth year (extension) of the award. In addition, in the past year, we performed transcriptome of foal peripheral blood mononuclear cells in the first month of life and adult horse cells. A summary of findings is reported below: Rebecca L. Tallmadge, Steven C. Miller, Stephen Parry, M. Julia B. Felippe. Equine neonatal vaccination induces measureable humoral immune responses in the first month of life. This manuscript is being finalized for submission to Clinical and Vaccine Immunology for publication. Abstract: Despite great need, the value of preventative neonatal vaccination strategies is controversial in veterinary medicine: concerns exist with the interference of passively transferred maternal antibodies and the level of immaturity of the innate and adaptive immune system at birth. We hypothesized that equine neonates generate a diverse antigen-specific immunoglobulin (Ig) response in response to vaccination, even in the presence of maternal antibodies. To test this hypothesis, foals were vaccinated in the neonatal period with keyhole limpet hemocyanin (KLH) or equine influenza vaccine and humoral immune responses were assessed until 42 days of life. Vaccination with keyhole limpet hemocyanin (KLH) at 3 and 21 days yielded a robust KLH-specific antibody response at 28 days of life. A separate group of foals was vaccinated with KLH in the presence of maternal KLH-specific antibodies. Endogenous KLH-specific antibodies were produced in these foals at day 28 as well, although a 10-fold difference (p = 0.068) in antibody concentration was measured when compared to the group of non-vaccinated dams. When investigating the Ig sequencing of isolated KLH-specific B lymphocytes from the vaccinated foal group, we observed an increase in Ig sequence diversity at days 35 and 42, which was significantly more diverse than non-selected Ig sequences (p = 0.002). However, these foal Ig sequences encoded less diversity than adult KLH-specific Ig sequences (p = 0.018). Endogenous foal serum IgG production in response to influenza vaccination was difficult to distinguish from circulating maternal antibodies, however, influenza-specific Ig sequences provided an alternative readout and revealed IgM and IgG diversity similar to that of KLH-specific B cells from adult horses. This work provides evidence of neonatal foals' ability to generate antigen-specific humoral immune responses to vaccination in the first month of life, regardless of the presence of maternal antibodies. Rebecca L. Tallmadge, Qi Sun, Minhui Wang, M. Julia B. Felippe.Transcriptome and functional analyses of equine neonatal peripheral blood leukocytes.This manuscript in its final phase of analyses and will be submitted toClinical and Vaccine Immunologyfor publication. The capacity of developing immunity is often questioned in the neonatal period. This study was undertaken to assess how neonatal foal monocyte-derived dendritic cells responded to antigen, and gather information about developmental aspects of foal peripheral blood mononuclear cells in the first month of life when compared to adult horse cells. In vitro dendritic cell cultures were performed for foal cells from day 3 and day 42, and adult horses (n=3 per group). We hypothesize that neonatal cells would generate a better response to whole pathogens, such as R. equi and E. coli in contrast to purified components of the pathogens, such as the VapA protein of R. equi and lipopolysaccharide (LPS) from E. coli. Gene expression measured using quantitative RT-PCR demonstrated that CD40 mRNA expression was increased with either whole pathogen or a pathogen fragment in comparison to non-stimulated samples at each time point. MHC class II DRA mRNA expression was not detected in the non-stimulated cells for 2 foals at day 3. For the third foal, DRA expression was not up-regulated by stimulation with whole pathogen or a respective pathogen fragment. By day 42, DRA mRNA expression was detected in all non-stimulated cells for all 3 foals, but again stimulation with whole pathogen or a respective pathogen fragment failed to up-regulate expression, with the exception of E.coli stimulation in one foal. For adult mares, one mare showed very robust up-regulation with stimulation, however the other mares had negligible changes in DRA gene expression. Altogether, substantial variation was found between individuals within each group. As for peripheral blood isolated leukocytes, day 3 (before vaccination) and day 42 (after 3 doses of vaccination with keyhole limpet hemocyanin, KLH, and influenza vaccine) cells were stimulated in vitro with influenza neuraminidase N8, KLH, phytohemagglutinin (PHA), or not-stimulated (NS) for 72 hours, and the expression cytokines IL-4 and IFN-gamma by CD4 T cells measured by flow cytometry; results did not detect a difference in the expression of cytokines from cells collected before and after vaccination, indicating a lack of recall response in the first month of life. Finally, the transcriptome of peripheral blood mononuclear cells was sequenced from foals at day 1 of life, from the same foals at 42 days of life, and adult horses (n=4 per group). Multidimensional scaling was performed to measure the relationship of the transcriptome profiles among samples. The foal samples from day 1 clustered together, whereas the foal samples from day 42 were more dispersed but closer to the adult horse samples. Differential gene expression tests were performed between the age groups and detected up-regulated and down-regulated genes, with adjusted p-values of p < 0.05 and fold difference > 2. Enrichment analysis was performed to determine biological processes affected by differential gene expression over time between foal samples from days 1 and 42, and between foal samples from day 42 and adult horses. Between days 1 and 42, 760 transcripts were affected within the response to stimulus group, whereas only 275 were affected between day 42 foals and adult horses. Further, the immune system process showed 331 differentially expressed transcripts between days 1 and 42 foals, and 121 between day 42 foals and adult horses. These data emphasizethe marked changes underway in the immune system of foals during the first 6 weeks of life, and our paired data (same foals sampled at day 1 and 42) provide powerful tracking of gene expression over time. What do you plan to do during the next reporting period to accomplish the goals? Nothing Reported

Impacts
What was accomplished under these goals? The Impact of our study: The data showed that antigen-specific immune responses can be generated in the first month of life in foals, in the presence of maternal antibodies, with a diverse and polyclonal repertoire that undergo isotype switching. The antigen-specific IgG sequence diversity in vaccinated foals was equivalent to that of vaccinated adult horses. Importantly, we observed that serum immunoglobulin concentration is not a sensitive method to measure foal humoral immune competence, and antigen-specific immunoglobulin sequencing provided additional means to measure humoral maturation and function. These data added to the understanding of immune response to vaccines inneonatal animals, and better understanding of developmental immunology. This is the first time that antigen-specific antibody response was measured at this level of detail in the equine neonate (or perhaps the neonate of any species). Importantly, this methodology can be tailored and applied to any species. The goal of this project was to evaluate neonatal immune responses to vaccines, based on B cell immunoglobulin heavy chain variable region (VDJ) sequence analysis, serum antibody levels, development of plasma and memory cells, and the function of antigen presenting cells in early life. Specifically, the proposed experiments investigated: 1) neonatal antibody production in response to protein vaccines; 2) how the neonatal response is improved with a vaccine booster; 3) how maternally-derived antibodies affect the production and diversity of neonatal antibodies; 4) neonatal antibody repertoire diversity; 5) neonatal cellular immune system recognition of vaccine antigens; and 6) progressive development of antigen presentation cells. One outstanding innovation brought by our study is the measurement of the immune response in the neonate using antigen-specific B-cell immunoglobulin variable region sequence, designed to detect with high sensitivity low levels of antigen-specific B cells and gene recombination, not possible in the young using the traditional serum antigen-specific antibody concentrations. This approach overcomes the challenge of measuring the confounding levels of maternally-derived antibodies during early age, and allows understanding of the effect of re-vaccination (booster) in the humoral immune response. Another is the transcriptome analyses of equine neonate leukocytes and comparisons with equine adult leukocytes that highlight key immune developmental characteristics in the neonatal phase. The following was accomplished under each specific aim: Aim 1a) Determine the extent of antigen-specific immunoglobulin diversity generated in response to neonatal vaccination & Aim 1b) Determine the neonatal humoral response to a vaccine booster using the same assays as aim 1a. Progress: These experiments demonstrated that neonatal foals generated a measurable and diverse antigen-specific IgG antibody response to KLH vaccinations and boosters within the first 6 weeks of life. Impact: The robust antigen-specific serum IgG antibodies detected at 28 days of life documented the earliest response to intramuscular vaccination in postnatal foals. Efficacious neonatal vaccination would provide a major contribution to improving the health of young livestock as well as herd health, as disease reservoirs could be decreased. Percentage of completion: 100 Aim 2a) Define the effect of maternal antibodies on the diversity of neonatal immunoglobulin production in response to vaccination & Aim 2b) Define the effect of maternal antibodies on the diversity of neonatal immunoglobulin production in response to vaccine booster. Progress: These experiments revealed that neonatal foals generated antigen-specific serum IgG responses to vaccination in the presence of circulating maternal antibodies. Further, the antigen-specific immunoglobulin nucleotide diversity of these responses was not statistically different from that of adult mares, indicating immunologic competence. Impact: The clear demonstration of neonatal foals' ability to mount robust antigen-specific humoral immune responses in the presence of maternal antibodies removed a barrier from instituting neonatal vaccination as a common practice. Percentage of completion: 100 Aim 3a) Determine the neonatal immune response to a commercially available vaccine used against a relevant pathogen & Aim 3b) Measure the effect of a vaccine booster on influenza-specific humoral responses. Progress: These experiments revealed that although endogenous soluble IgG response to influenza vaccination was difficult to distinguish from passively-transferred maternal antibodies over 42 days of life, influenza-specific B cells expressing IgM or IgG were identified in these foals. Impact: Antigen-specific immunoglobulin sequencing was a more sensitive test to detect low levels of endogenously-produced antibodies, not possible previously. Percentage of completion: 100 Aim 3c) Assess the development of influenza-specific memory B cells in vaccinated neonates. Progress: These experiments indicated that detection of lymphocyte memory cell response in the peripheral blood using mRNA expression of CD38 and CD27 was limited at 42 days of life, and subsequent samples at older age would be informative of the effect of age and circulating maternal antibodies in immunologic memory development. Impact: Detection of antigen-specific memory B cell responses in the first 6 weeks of life was inconsistent and limited; longer period of study would be more informative. Percentage of completion: 100 Aim 3d) Investigate the neonatal cellular immune response to a vaccine booster using lymphocyte proliferation and cytokine production assays. Progress: In these experiments, no statistically significant differences were detected amongst the groups in response to antigenic stimulation in vitro, indicating that expansion of CD4 memory cells was limited at this age despite 3 vaccinations. Impact: Detection of antigen-specific CD4 lymphocyte memory cell responses in the first 6 weeks of life was limited; longer period of study would be more informative. Percentage of completion: 100 Aim 4a) Identify developmentally-regulated gene expression changes in APCs when exposed to inactivated whole influenza organism or its fragment & Aim 4b) Contrast the gene expression profiles identified in aim 4a with adult APC response to the same stimuli. Progress: Overall, the data indicated that individuals differed in their responses to pathogen stimulation (whole pathogen versus fragment, and type of pathogen/structure). Due to the extensive variation among individuals, more samples are needed in each group to increase statistical power. Transcriptome data illustrated the marked dynamics underway in the immune system of foals during the first 6 weeks of life, both at the level of individual genes and biological processes. Our paired data (same foals sampled at day 1 and 42) provided this powerful insight and allowed kinetic analysis of gene expression. Impact: The extensive variation in response to pathogen structure stimulation among individuals has relevance to developing vaccines that are effective across populations. Inclusion of multiple pathogen structures in vaccine products may increase the number of individuals that respond to vaccination. Detailed knowledge of immune gene expression kinetics during early life derived from transcriptome studies will further inform effective vaccine response and our understanding of the development of the immune system. Percentage of completion: 100

Publications

  • Type: Journal Articles Status: Other Year Published: 2016 Citation: Rebecca L. Tallmadge, Steven C. Miller, Stephen Parry, M. Julia B. Felippe. Equine neonatal vaccination induces measurable humoral immune responses in the first month of life. Clinical and Vaccine Immunology.
  • Type: Journal Articles Status: Other Year Published: 2016 Citation: Rebecca L. Tallmadge, Qi Sun, Minhui Wang, M. Julia B. Felippe. Transcriptome and functional analyses of equine neonatal peripheral blood leukocytes. Clinical and Vaccine Immunology.
  • Type: Conference Papers and Presentations Status: Published Year Published: 2015 Citation: Tallmadge RL, Felippe MJB. Assessing neonatal responses to vaccination at the protein and gene level: Ig and more Ig. Plant & Animal Genome Conference, PAG XXII, San Diego, CA.
  • Type: Conference Papers and Presentations Status: Published Year Published: 2015 Citation: Tallmadge RL, Felippe MJB. Equine neonatal immunoglobulin production and diversity in response to vaccination. 5TH European Veterinary Immunology Workshop, Vienna, Austria.


Progress 05/01/14 to 04/30/15

Outputs
Target Audience: Scientists, veterinarians, equine industry, animal production industry, professional students Changes/Problems: Despite intermittent technical difficulties with the FACS sorting equipment in our core facility, we had a delay but were successful in finishing the antigen-specific B cell sorting experiments. Another difficulty was the instability of the equine influenza protein expressed from a baculovirus system but we identified an alternate source of equine influenza protein (N8 neuranimidase, ATCC) that worked very well in the different assays needed. One change in the protocol was the antigen-specific single-B cell culture because the poor viability of the cells after FACS sorting; instead, we are stimulating unsorted cells with the antigen in vitro. What opportunities for training and professional development has the project provided? We learned about a reliable purified influenza N8 neuranimidase protein source (ATCC) that is useful for antigen-specific B cell sorting, ELISA and in vitro stimulation; the experiments using this portein were robust. We also learned how to overcome antigen-specific immunoglobulin sequencing without the single-cell culture. How have the results been disseminated to communities of interest? We presented our results at2014 AFRI Animal Health and Disease, Animal Well-Being, Food Security, Ecology & Evolution of Infectious Diseases and Dual Purpose with Dual Benefit Awardee Virtual Meeting, Nov 19-21, 2014. What do you plan to do during the next reporting period to accomplish the goals? Complete the in vitro recall antigen response (proliferation) assays, analyse data and finish manuscript#1 for publication, complete the in vitro and transcriptome experiments that measure dendritic cell competence in the foal, complete immunoglobulin RT-PCR and sequencing, complete immunoglobulin RT-PCR for memory markers, analyse data and prepare manuscript #2 for publication.

Impacts
What was accomplished under these goals? Aim 1a) Determine the extent of antigen-specific immunoglobulin diversity generated in response to neonatal vaccination & Aim 1b) Determine the neonatal humoral response to a vaccine booster using the same assays as aim 1a. Foal and mare multiple (primary and booster) vaccination with KLH protein and multiple blood sampling completed; KLH-specific B cell sorting using flow cytometry completed; KLH-specific ELISAs to measure antibody response completed; sequencing of KLH-specific B cell immunoglobulin variable region in progress. The effect of boosters on humoral response is under analyses. Aim 2a) Define the effect of maternal antibodies on the diversity of neonatal immunoglobulin production in response to vaccination & Aim 2b) Define the effect of maternal antibodies on the diversity of neonatal immunoglobulin production in response to vaccine booster. The results of the assays (extent of diversity, KLH immunoglobulin levels and isotypes) are under analyses to determine the effect of maternal antibodies on the neonate's antigen-specific humoral response. Aim 3a) Determine the neonatal immune response to a commercially available vaccine used against a relevant pathogen & Aim 3b) Measure the effect of a vaccine booster on influenza-specific humoral responses. Foal and mare multiple (primary and booster) vaccination with influenza protein and multiple blood sampling completed; influenza-specific B cell sorting using flow cytometry completed; influenza-specific ELISAs to measure antibody response completed; sequencing of influenza-specific B cell immunoglobulin variable region sequencing in progress. Analyses of the effect of boosters on humoral response will follow in a timely manner. Aim 3c) Assess the development of influenza-specific memory B cells in vaccinated neonates. Influenza-specific B cell sorting using flow cytometry completed; quantitative RT-PCR to measure expression of memory cell markers CD27 and CD38 in progress. Aim 3d) Investigate the neonatal cellular immune response to a vaccine booster using lymphocyte proliferation and cytokine production assays. In vitro stimulation of influenza-specific circulating T cells with influenza protein and cytokine analyses in progress. Aim 4a. Identify developmentally-regulated gene expression changes in APCs when exposed to inactivated whole influenza organism or its fragment. In vitro neonatal antigen presenting cell differentiation and stimulation with different organisms or their fragments in progress; transcriptome analysis to identify gene expression profiles of APCs in response to stimulation will follow once samples are harvested and processed.

Publications


    Progress 05/01/13 to 04/30/14

    Outputs
    Target Audience: Scientists, equine industry, animal production industry, professional students Changes/Problems: No major changes; we had some technical challenges with cell viability after cell sorting uisng flow cytometry but we were able to optimize the technique. What opportunities for training and professional development has the project provided? We have gained experience in performing, troubleshooting, and comparing cell-sorting methods (flow cytometry and magnetic cell sorting). We are now confident in our expectations of number of antigen-specific cells likely to be identified and sorted. How have the results been disseminated to communities of interest? We reported our current findings to the scientific community in the 2013 USDA-NIFA AFRI Animal Health & Animal Well-being Project Director Workshop at College Park, MD. What do you plan to do during the next reporting period to accomplish the goals? For the next reporting period: a) finish sampling collection of control non-vaccinated mares and foals in the 2014 foaling season; b) finish the RT-PCR, sequencing and ELISA analyses of collected samples; c) perform the in vitro recall antigen response (proliferation) assays; d) perform the in vitro and transcriptome experiments that measure dendritic cell competence in the foal; e) finalize statistical analyses; and d) prepare manuscripts for consideration of publication.

    Impacts
    What was accomplished under these goals? In the past year (5/1/13 – 4/30/14), we vaccinated the remaining mares and foals with KLH and influenza vaccines and collected serum and blood samples at the specified collection dates. Samples were processed and frozen for future use. We chose to assess responses to KLH vaccination first and so the KLH ELISA was performed on mare and foal serum samples. The KLH ELISA results revealed serum immunoglobulin responses to the KLH immunogen by foals at 28 days of life. Sequencing of the immunoglobulin variable region of KLH-specific B lymphocytes has been performed for some foals, but not all foals yet. We are currently preparing to perform the influenza ELISA on stored mare and foal serum samples. In the next month, we plan to initiate the cell culture, stimulation, and RNA-Seq experiments outlined in aim 4.

    Publications


      Progress 05/01/12 to 04/30/13

      Outputs
      Target Audience: Target audience; scientists, equine industry, animal production industry, professional students Changes/Problems: No major changes; we had some technical challenges with cell viability after cell sorting uisng flow cytometry but we were able to optimize the technique. What opportunities for training and professional development has the project provided? We obtained significant training in the ELISAs and immunoglobulin variable region gene sequencing and analysis. How have the results been disseminated to communities of interest? We reported the ELISA to the scienific community in the 2012 USDA-NIFA AFRI Animal Health and Animal Welfare Project Director Workshop. What do you plan to do during the next reporting period to accomplish the goals? For the next reporting period: a) finish sampling collection of control non-vaccinated mares and foals in the 2014 foaling season; b) finish the RT-PCR, sequencing and ELISA analyses of collected samples; c) perform the in vitro recall antigen response (proliferation) assays; d) perform the in vitro and transcriptome experiments that measure dendritic cell competence in the foal; e) finalize statistical analyses; and d) prepare manuscripts for consideration of publication.

      Impacts
      What was accomplished under these goals? By the time the award was granted (May 2012), the foaling season and expected foalings at the Cornell Equine Park were mostly finished. We were able to take full advantage of the 2013 foaling season and markedly advanced the vaccination and sampling collection phases, essential for the experimental assays. For this past year, we were able to a) establish a method using single-cell sorting and RT-PCR/sequencing for KLH-specific B cells for sequencing of the immunoglobulin variable region; b) establish the KLH and influenza ELISA tests to measure antigen-specific serum immunoglobulins; that also included the expression of influenza antigen for the assay in collaboration with Dr. Colin Parrish; c) vaccinated mares (2 doses before foaling) and foals (days 3, 21 and 35 of life) with KLH and influenza vaccines according to their groups; and collected blood samples (mares: before vaccination and 3 days after foaling; foals: before suckling, days 3, 21, 28, 35 and 42 of life); d) stored sera and isolated and stored leukocytes of all samples collected; and e) currently performing the single B cell sorting and RT-PCR, sequencing and ELISA.

      Publications